Therapeutics Acquisition Corp. Closes $135.7 Million IPO

The Technology and Special Purpose Acquisition Companies (SPACs) teams advised Therapeutics Acquisition Corp. (Nasdaq: TXAC) on the closing of its initial public offering of 13,570,000 shares of Class A common stock, including 1,770,000 shares issued pursuant to the exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per share, resulting in gross proceeds of $135,700,000. 

Sponsored by RA Capital Management, L.P., Therapeutics Acquisition Corp. is a blank check company formed for the purpose of effecting a business combination with one or more businesses in the healthcare industry. The proceeds of the offering will be used to fund such business combination.

The Goodwin team was led by Jocelyn Arel, Dan Espinoza, Michael Rosenberg, Eryn Mathews and Yifan Yang and included Todd Pollack, Andy Barton, Chukwudi Udeogalanya, Michelle Wilensky, Mike Minahan, Sonia Wu and Adam Romig. 

For additional details on the closing, please read the press release.